Cervene (Nalmefene) in acute ischemic stroke: Final results of a phase III efficacy study

Stroke

Volumn 31, Issue 6, 2000, Pages 1234-1239

  Clark, Wayne M ^a,d   Raps, Eric C ^e   Tong, David C ^b   Kelly, Roger E ^c  

^a Oregon Stroke Center   (United States)

^b Stanford California and Cofounder   (United States)

^c LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e NONE

Author keywords

Narcotic antagonists; Stroke; Therapy

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID; NALMEFENE; OPIATE ANTAGONIST; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; AGITATION; ARTICLE; CENTRAL NERVOUS SYSTEM FUNCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; GLASGOW COMA SCALE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROPROTECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT OUTCOME; VERTIGO; VOMITING;

EID: 0034034434     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.31.6.1234     Document Type: Article

References (39)

1. Rothman S, Olney J. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann NeuroL 1986;19:105-111.
2. Olney JW. Excitotoxins: an overview. In: Fuxe K, Roberts PJ, Schwarcz R, eds. Excitotoxins. London, UK: McMillan Press; 1983:92-96.
3. Faden AI. Neuropeptides and central nervous system injury. Arch Neurol. 1986;43:501-504.
4. Zivin JA, Choi DW. Stroke therapy. Sci Am. 1991;July:56-63.
5. Albers G, Clark W, Atkinson R, Madden K, Barbut D, Lechtenberg R, Whitehouse M. Dose escalation study of the NMDA glycine-site antagonist ACEA 1021 in acute ischemic stroke. Stroke. 1997;28:271.
6. Grotta J, Hantson L, Wessel T. The efficacy and safety of lubeluzole in patients with acute ischemic stroke. Stroke. 1997;28:271.
7. Edwards K, for the CNS 1102-008 Study Group. Cerestat in the treatment of acute ischemic stroke: results of a phase II trial. Neurology. 1996; 46:424.
8. Grotta J, Clark W, Coull B, Pettigrew C, Mackay B, Goldstein L, Meissner I, LaRue L. Safety and tolerability of the glutamate antagonist CGS 19755 (selfotel) in patients with acute ischemic stroke: results of a phase II randomized trial. Stroke. 1995;26:602-605.
9. Albers G, Atkinson R, Kelley R, Rosenbaum R. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke. 1995;26:254-258.
10. Davis S, for the ASSIST Collaborative Group. Acute stroke studies involving selfotel treatment. Stroke. 1997;28:271.
11. Faden AI, Role of opiate antagonists in the treatment of stroke. In: Weinstein PR, Faden AI, eds. Protection of the Brain From Ischemia. Baltimore, Md: Williams & Wilkins; 1990:265-271.
12. Krumins SA, Faden AI. Traumatic injury alters opiate receptor binding in spinal cord. Ann Neurol. 1986;19:498-501.
13. Herman BH, Goldstein A. Antinociception and paralysis induced by intrathecal dynorphin A. J Pharmacol Exp Ther. 1985;232:27-32.
14. Faden AI, Molineaux CJ, Rosenberger JG, Jacobs TP, Cox BM. Increased dynorphin immunoreactivity in spinal cord after traumatic injury. Regul Pept. 1985;11:35-41.
15. Scavini S, Rozza A, Bo P, Lanza E, Favalli L, Savoldi F, Racagni G. κ-Opioid receptor changes and neurophysiological alterations during cerebral ischemia in rabbits. Stroke. 1990;21:943-947.
16. Harini RJ, Supra EL, Roberts JP, Lavyne MH. Effect of naloxone on cerebral perfusion and cardiac performance during experimental cerebral ischemia. J Neurosurg. 1986;64:780-786.
17. 5)-enkephalinamide, and naloxone on cortical blood flow and cerebral blood volume in experimental brain ischemia in anesthetized cats. J Cereb Blood Flow Metab. 1986;6: 553-558.
18. Namba S, Nishigaki S, Fujiwara N, Wani T, Namba Y, Masaoka T. Opiate-antagonist reversal of neurological deficits: experimental and clinical studies. Jpn J Psych Neurol. 1986;40-61-79.
19. Fallis RJ, Fisher M, Lobo RA. A double blind trial of naloxone in the treatment of acute stroke. Stroke. 1984;15:627-629.
20. Perraro F, Tosocini G, Pertoldi F, Pertoldi F, Sbrojavacca R, Beorchia A, Bulfoni A, Del Fabbro L, Grassi L, Lestuzzi A, Mione V. Double-blind placebo controlled trial of naloxone on motor deficits in acute cerebrovascular disease. Lancet. 1984;1:915.
21. Hahn EF, Fishman J, Heilman RD. Narcotic antagonists.4.carbon-6 derivatives of N-substituted noroxymorphones as narcotic antagonists. J Med Chem. 1975;18:259-262.
22. Michel ME, Bolger G, Weissman BA. Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Pharmacologist. 1984;26:201.
23. Yum SW, Faden AI. Comparison of the neuroprotective effects of the N-methyl-D-aspartate antagonist MK801 and the opiate receptor antagonist nalmefene in experimental spinal cord ischemia. Arch Neurol. 1990; 47:277-281.
24. Faden AI, Shirane R, Chang LH, James TL, Lemke M, Weinstein PR. Opiate-receptor antagonist improves metabolic recovery and limits neurochemical alterations associated with reperfusion after global brain ischemia in rats. J Pharmacol Exp Ther. 1990;255:451-460.
25. Graham SH, Shimizu H, Newman A, Weinstein P, Faden Al. Opioid receptor antagonist nalmefene stereospecifically inhibits glutamate release during global cerebral ischemia. Brain Res. 1993;632:346-350.
26. 2+. bioenergetic state, and neurologic outcome following traumatic brain injury in rats. J Neurosci. 1990;10:3524-3530.
27. Clark W, Coull B, Karukin M, Hendin B, Kelley R, Rosing H, Zachariach S, Winograd M, Raps E Walshe T, Singer S, Mettinger K. Randomized trial of Cervene, a κ receptor-selective opioid antagonist, in acute ischemic stroke. J Stroke Cerebrovasc Dis. 1996;6:35-40.
28. Clark W, Ertag W, Orecchio E, Raps E. Cervene in acute ischemic stroke: results of a double-blind, placebo-controlled, dose-comparison study. J Stroke Cerebrovasc Dis. 1999;8:224-230.
29. Mahoney F, Barthel D. Functional evaluation: Barthel Index. Md State Med J. 1965;14:61-65.
30. Jennett B, Bond M. Assessment of outcome after severe brain damage: a practical scale. Lancet. 1975;1:480-484.
31. Brott T, Adams H, Olinger C. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864-870.
32. Lyden P, Brott T, Tilley B, Welch K, Mascha E, Levine S. Haley E, Grotta J, Marler J. Improved reliability of NIH Stroke Scale using video training. Stroke. 1994;25:2220-2226.
33. Adams H, Bendixen B, Kappelle J, Biller J, Love B, Gordon D, Marsh E. Classification of subtype of acute ischemic stroke. Stroke. 1993;24: 35-41.
34. Clark W, Williams B, Selzer K, Zweifler R, Sabounjian L, Gammans R, for the Citicoline Stroke Study Group. A randomized efficacy trial of citicoline in acute ischemic stroke patients. Stroke. 1999;30:2592-2597.
35. Clark W, Wissman S, Albers G, Jhamandas J, Madden K, Hamilton S. The ATLANTIS study: recombinant tissue plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: a randomized, double-blind, placebo-controlled trial. JAMA. 1999;282: 2019-2026.
36. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
37. Clark WM, Coull BM, for the CGS19755 Study Group. Randomized trial of CGS19755. a glutamate antagonist, in acute ischemic stroke treatment. Neurology. 1994;44;A270. Abstract.
38. Albers GW, Atkinson RP, Kelley RE, Rosenbaum DM, for the Dextrorphan Study Group. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with an acute stroke. Stroke. 1995;26:254-258.
39. Lesko L, for the Cerestat Stroke Study Group. A pivotal phase III efficacy and safety study of cerestat in acute stroke patients. Stroke. 1997;28:232.